Drug Eruption and Interactions - PHARMACEUTICAL REVIEW
Share Embed Flag
Download ePaper

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

pharmareview.files.wordpress.com
from pharmareview.files.wordpress.com More from this publisher
02.06.2013 Views

CALFACTANT Trade name: Infasurf (Forest) Indications: Prevention of respiratory distress syndrome Category: Pulmonary surfactant Half-life: N/A Skin Cyanosis 65% CANDESARTAN Reactions Trade names: Amias; Atacand (AstraZeneca) Indications: Hypertension Category: Angiotensin II receptor antagonist Half-life: 9 hours Reactions Skin Angioedema (2003): Hille K+, Am J Ophthalmol 135(2), 224 (2002): Lo KS, Pharmacotherapy 22(9), 1176 Diaphoresis (>0.5%) Edema Erythema multiforme (2004): Ejaz AA+, South Med J 97(6), 614 Exanthems (1%) Perleche (2004): Chen C+, Nephrologie 25(3), 97 Psoriasis (2003): Kawamura A+, Eur J Dermatol 13(4), 406 Rash (sic) (>0.5%) (2004): Morton A+, BMJ 328(7430), 25 Mucosal Aphthous stomatitis (2004): Chen C+, Nephrologie 25(3), 97 Burning mouth syndrome (2004): Chen C+, Nephrologie 25(3), 97 Stomatitis (2004): Chen C+, Nephrologie 25(3), 97 Eyes Glaucoma (2003): Hille K+, Am J Ophthalmol 135(2), 224 Other Abdominal pain (2003): Basile G+, J Clin Gastroenterol 36(3), 273 Cough (2002): Cuspidi C+, JHypertens20(11), 2293 Myalgia/Myositis/Myopathy/Myotoxicity (>0.5%) Upper respiratory infection (2004): Gleiter CH+, Cardiovasc Drug Rev 22(4), 263 CAPECITABINE Trade name: Xeloda (Roche) Indications: Metastatic breast cancer Category: Antimetabolite; Antineoplastic Half-life: 0.5–1 hour Reactions CAPECITABINE 85 Skin Acral erythema Dermatitis (37%) (2003): Wagstaff AJ+, Drugs 63(2), 217 (25%) (1999): Dooley M+, Drugs 58, 69 Diaphoresis (0.2%) Edema (9%) (1996): Bajetta E+, Tumori 82, 450 Erythema Exfoliative dermatitis (31–37%) Hand–foot syndrome (7–58%) (2006): Blum JL+, J Clin Oncol 24(27), 4384 (with paclitaxel) (2006): Crane CH+, J Clin Oncol 24(7), 1145 (2006): Gressett SM+, J Oncol Pharm Pract 12(3), 131 (2006): Kara IO+, Breast 15(3), 414 (with docetaxel) (2006): Lin EH+, Am J Clin Oncol 29(3), 232 (2006): Saif MW+, Clin Colorectal Cancer 6(3), 219 (2006): Sharma R+, Br J Cancer 94(7), 964 (22%) (2006): Wolf JK+, Gynecol Oncol 102(3), 468 (2006): Yamaguchi K+, Gan To Kagaku Ryoho 33(7), 891 (13%) (2006): Yerushalmi R+, JSurgOncol93(7), 529 (2%) (2005): Levy C+, Cancer Treat Rev 31 Suppl 4, S17 (2005): Ramanathan RK+, Cancer Chemother Pharmacol 55(4), 354 (2005): Rini BI+, Cancer 103(3), 553 (2005): Walko CM+, Clin Ther 27(1), 23 (2005): Wilkes GM+, Clin J Oncol Nurs 9(1), 103 (2004): Guo L+, Zhonghua Zhong Liu Za Zhi 26(4), 250 (2004): Heo YS+, J Clin Pharmacol 2004 Oct 44(10), 1166 (2004): Hofheinz RD+, Br J Cancer 91(5), 834 (3%) (2004): Hong YS+, Ann Oncol 15(9), 1344 (9%) (2004): Lassere Y+, Eur J Oncol Nurs 8 Suppl 1, S31 (2004): Lebowitz PF+, Clin Cancer Res 10(20), 6764 (2004): Lee JJ+, Jpn J Clin Oncol 34(7), 400 (35%) (2004): Lokich J, Cancer Invest 22(5), 713 (8%) (2004): Mackey JR+, Clin Breast Cancer 5(4), 287 (30%) (2004): Marse H+, Eur J Oncol Nurs 8 Suppl, S16 (2004): Morant R+, Br J Cancer 90(7), 1312 (2004): Narasimhan P+, Cutis 73(2), 101 (3 cases) (2004): Park SH+, Oncology 66(5), 353 (2004): Park YH+, Br J Cancer 90(7), 1329 (50%) (2004): Pierga JY+, Breast Cancer Res Treat 88(2), 117 (2004): Rao S+, Br J Cancer 91(5), 839 (19.7%) (with mitomycin) (2004): Sakamoto J+, Anticancer Drugs 15(2), 137 (62%) (2004): Scheithauer W+, Oncology (Williston Park) 18(9), 1161 (2004): Sternberg CN+, Eur J Oncol Nurs 8 Suppl, S4 (2003): Chua DT+, Oral Oncol 39(4), 361 (58.8%) (2003): Gerbrecht BM, Cancer Nurs 26(2), 161 (2003): Han JY+, Cancer 98(9), 1918 (33%) (with docetaxel) (2003): Jones KL+, Pharmacotherapy 23(8), 1076 (2003): Kalbakis K+, Int J Radiat Oncol Biol Phys 56(5), 1284 (1 case) (2003): Makhnova EV+, Vopr Onkol 49(2), 193 (2003): Risum S+, Ugeskr Laeger 165(33), 3161 (2003): Scheithauer W+, Ann Oncol 14(12), 1735 (2003): Vasey PA+, Br J Cancer 89(10), 1843 (2003): Wagstaff AJ+, Drugs 63(2), 217 (25%) (2002): Abushullaih S+, Cancer Invest 20(1), 3 (68.3%)

86 CAPECITABINE (2002): Dunst J+, J Clin Oncol 20(19), 3983 (2002): Lin E+, Oncology 16(12 Suppl No 14), 31 (2002): Liu X+, Zhonghua Zhong Liu Za Zhi 24(1), 71 (2002): O’Shaughnessy J+, J Clin Oncol 20(12), 2812 (2002): Rothenberg ML, Oncology 16(12), 16 (2002): Scheithauer W+, Ann Oncol 13(10), 1583 (2002): Wenzel C+, Am J Kidney Dis 39(1), 48 (7.7%) (2001): Chang DZ+, Cancer Chemother Pharmacol 48(6), 493 (67%) (2001): Elasmar SA+, Jpn J Clin Oncol 31(4), 172 (passim) (2001): Hoff PM+, J Clin Oncol 19(8), 2282 (2001): McGavin JK+, Drugs 61(15), 2309 (2001): O’Shaughnessy JA+, Ann Oncol 12(9), 1247 (2001): Seitz JF, Semin Oncol 28(1 Suppl 1), 41 (1999): Blum JL, Oncology 57, 16 (1999): Blum JL+, J Clin Oncol 17, 485 (10%) (1999): Dooley M+, Drugs 58, 69 (1999): Mrozek-Orlowski ME+, Oncol Nurs Forum 26, 753 (1999): Villalona-Calero MA+, J Clin Oncol 17(6), 1915 (with paclitaxel) (1998): Budman DR+, J Clin Oncol 16, 1795 Photo-recall (

86 CAPECITABINE<br />

(2002): Dunst J+, J Clin Oncol 20(19), 3983<br />

(2002): Lin E+, Oncology 16(12 Suppl No 14), 31<br />

(2002): Liu X+, Zhonghua Zhong Liu Za Zhi 24(1), 71<br />

(2002): O’Shaughnessy J+, J Clin Oncol 20(12), 2812<br />

(2002): Rothenberg ML, Oncology 16(12), 16<br />

(2002): Scheithauer W+, Ann Oncol 13(10), 1583<br />

(2002): Wenzel C+, Am J Kidney Dis 39(1), 48 (7.7%)<br />

(2001): Chang DZ+, Cancer Chemother Pharmacol 48(6), 493<br />

(67%)<br />

(2001): Elasmar SA+, Jpn J Clin Oncol 31(4), 172 (passim)<br />

(2001): Hoff PM+, J Clin Oncol 19(8), 2282<br />

(2001): McGavin JK+, <strong>Drug</strong>s 61(15), 2309<br />

(2001): O’Shaughnessy JA+, Ann Oncol 12(9), 1247<br />

(2001): Seitz JF, Semin Oncol 28(1 Suppl 1), 41<br />

(1999): Blum JL, Oncology 57, 16<br />

(1999): Blum JL+, J Clin Oncol 17, 485 (10%)<br />

(1999): Dooley M+, <strong>Drug</strong>s 58, 69<br />

(1999): Mrozek-Orlowski ME+, Oncol Nurs Forum 26, 753<br />

(1999): Villalona-Calero MA+, J Clin Oncol 17(6), 1915 (with<br />

paclitaxel)<br />

(1998): Budman DR+, J Clin Oncol 16, 1795<br />

Photo-recall (

logo

products

Resources

Company

Terms of service
Privacy policy
Cookie policy
Cookie settings
Imprint
Change language
Made with love in Switzerland
© 2024 Yumpu.com all rights reserved

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!